Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 07 02 2020
accepted: 12 05 2020
pubmed: 23 5 2020
medline: 12 1 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Women over 70 with early breast cancer treated with breast-conserving surgery are typically offered adjuvant endocrine and radiation therapy. Prior studies have supported the omission of adjuvant radiation in this low-risk population. We sought to compare the effect of adjuvant treatment with endocrine therapy alone, radiation therapy alone or both versus no adjuvant treatment on local control and survival in this population. Data were extracted on 1363 breast cancer patients over the age of 70 treated with a breast-conserving surgery from 2003 until 2018. 460 patients met inclusion criteria of pT1N0, invasive disease with negative margins and not treated with chemotherapy. The primary outcome of this population-based study was local recurrence-free survival at 5 and 10 years. Patients receiving no adjuvant therapy had worse local recurrence-free, loco-regional recurrence-free and disease-free survival than patients receiving at least one form of adjuvant therapy (p < 0.05). 5-year local recurrence rates were 0.8% in patients receiving both endocrine and radiation therapy, 1.5% in those receiving radiation alone, 4.2% in those receiving endocrine therapy alone and 12% in those receiving no adjuvant therapy. This study supports the benefit of some form of adjuvant therapy (radiation alone, endocrine therapy alone or both) in low-risk breast cancer patients over 70. Receiving no adjuvant therapy is associated with poorer outcomes. Many of these patients are candidates for Accelerated Partial Breast Irradiation which can be completed in less than a week. These patients should be offered radiation therapy, endocrine therapy or both.

Identifiants

pubmed: 32441018
doi: 10.1007/s10549-020-05691-6
pii: 10.1007/s10549-020-05691-6
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

411-420

Auteurs

Hannah Dahn (H)

Department of Radiation Oncology, Dalhousie University, 5820 University Avenue, Halifax, NS, B3H 1V7, Canada.

Derek Wilke (D)

Department of Radiation Oncology, Dalhousie University, 5820 University Avenue, Halifax, NS, B3H 1V7, Canada.

Gordon Walsh (G)

Cancer Registry & Analytics Unit, NSHA Cancer Care Program, QEII Health Sciences Centre, Room 556, Bethune Building, 1276 South Park Street, Halifax, NS, B3H 2Y9, Canada.

Jean-Philippe Pignol (JP)

Department of Radiation Oncology, Dalhousie University, 5820 University Avenue, Halifax, NS, B3H 1V7, Canada. Jean-Philippe.Pignol@nshealth.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH